Réaction #66081

ord-ed1bbed5db284f9d970626265a2f85cf

Équation de réaction

Brc1cccc2c3c([nH]c12)C1CCN(CC1)C3
product
Brc1cccc2c3c([nH]c12)C1CCN(CC1)C3
7-bromo-3,4,5,6-tetrahydro-1H-2,5-ethanoazepino[4,3-b]indole
C=Cc1cncnc1
product
C=Cc1cncnc1
5-vinylpyrimidine
O=S(=O)([O-])[O-].[Mg+2]
magnesium sulfate
C(=C\c1cccc2c3c([nH]c12)C1CCN(CC1)C3)/c1cncnc1
title compound
C(=C\c1cccc2c3c([nH]c12)C1CCN(CC1)C3)/c1cncnc1
7-[(E)-2-(pyrimidin-5-yl)vinyl]-3,4,5,6-tetrahydro-1H-2,5-ethanoazepino[4,3-b]indole

Conditions de réaction

Conditions détaillées
See reaction.notes.procedure_details.

Mode opératoire

The product of Example 1B (265 mg, 0.91 mmol), the product of Example 29A (193 mg, 1.82 mmol) and magnesium sulfate (55 mg, 0.46 mmol) were combined and processed as described in Example 1D to provide the title compound as the slower eluting compound: 1H NMR (400 MHz, methanol-d4) δ ppm 2.04-2.20 (m, 4 H), 3.04-3.17 (m, 3 H), 3.22-3.30 (m, 2 H), 4.26 (s, 2 H), 7.05 (t, J=7.6 Hz, 1 H), 7.24 (d, J=16.8 Hz, 1 H), 7.31 (dd, J=7.9, 0.9 Hz, 1 H), 7.43-7.47 (m, J=7.3 Hz, 1 H), 7.89 (s, 1 H), 9.02 (d, J=16.1 Hz, 1 H), 9.04 (s, 2 H); MS (APCI) m/z 317 (M+H)+.

Source

DOI: 10.6084/m9.figshare.5104873.v1Brevet: US08524703B2uspto-grants-2013_09